and other tissue types (Fig. 2). The company is proceeding with additional capsid campaigns derived from AAV9, AAV5, and other AAV serotypes to identify novel capsids optimized for AAV delivery ...

However, the tropism (selective tissue targeting) of AAVs isolated from nature is one shortcoming, Bu notes. “The tropism of natural AAV serotypes is limited,” he says. “They also tend to ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

2 However, not all vectors have equivalent properties, with some possessing higher packaging capacities, delivery efficiencies, tissue specificities, and immunogenicity. 4 For instance, different AAV ...

Mariella is an assistant editor at The Scientist. She has a background in neuroscience, and her work has appeared in Drug Discovery News and Massive Science. View Full Profile. Learn about our ...

In fact, a variety of AAV serotypes can be used to achieve different tissue tropism, efficacy and drug delivery effects. Due to their diversity, and the need to remove process-related impurities, the ...

the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately 70% of the AAV gene therapy market, with AAV2 being the most prevalent serotype in clinical ...

The intra-tissue injection is invasive and ... including long vector transit distances. Recombinant AAV administration, including serotypes, promoters, and enhancers, can cause side effects ...

This approach, thanks to its easy applicability to multiple AAV serotypes, reduced processing steps, and comparable genome recovery rates, seems well-positioned to edge out immunoaffinity ...

The optimized NanoCas, the authors say, “exhibits potent editing capabilities across various cell systems and tissues in vivo when administered via adeno-associated viral (AAV) vectors.” ...

demonstrating its ability to perform gene editing in non-liver tissues, including skeletal muscle, using a single adeno-associated virus (AAV) vector. Experiments in non-human primates (NHPs ...

Asimov, the synthetic biology company advancing the design and production of therapeutics, today announced the launch of the ...